Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
74.81
+1.31 (1.78%)
Oct 29, 2025, 3:49 PM EDT - Market open
Company Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania
Palvella Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Wesley Kaupinen |
Contact Details
Address: 125 Strafford Avenue, Suite 360 Wayne, Pennsylvania 19087 United States | |
| Phone | 484 253 1461 |
| Website | palvellatx.com |
Stock Details
| Ticker Symbol | PVLA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001742961 |
| CUSIP Number | 697947109 |
| ISIN Number | US6979471090 |
| Employer ID | 81-2228053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wesley Kaupinen | Chief Executive Officer |
| Matthew Korenberg | Chief Financial Officer |
| Kathleen Goin | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2022 | D | Notice of Exempt Offering of Securities |
| Jun 3, 2020 | D | Notice of Exempt Offering of Securities |
| Aug 12, 2019 | D/A | Filing |
| Apr 12, 2019 | D | Notice of Exempt Offering of Securities |
| Jun 14, 2018 | D | Notice of Exempt Offering of Securities |